Databricks and NVIDIA have launched Genesis Workbench, a modular, open blueprint that centralizes GPU-accelerated AI tools for life sciences R&D into a single, governed environment, targeting core blockers in drug discovery such as fragmented toolchains, data security risks, and the need for no-code access. The platform integrates NVIDIA BioNeMo, Parabricks, CUDA-X, and a catalog of biology and chemistry models, orchestrated through Databricks' Unity Catalog, MLflow, and serverless GPU compute, enabling bench scientists to execute tasks using a no-code interface while maintaining strict IP governance. According to Futurum Group's 1H 2026 AI Platforms Decision Maker Survey (n=820), 53% of organizations cite privacy and security as top GenAI adoption challenges, highlighting why in-perimeter, API-free architectures are gaining traction. Genesis Workbench challenges the dominant vertical SaaS model by offering a modular, open-source blueprint that organizations can deploy on their own governed data, eliminating external API dependencies and centralizing governance with Unity Catalog.